Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOR NASDAQ:BPTSY NASDAQ:HEPA NYSE:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.10$660K1.1286,634 shs16,292 shsBPTSYBiophytis$2.00$1.83$1.33▼$5.97$702K0.861,668 shsN/AHEPAHepion Pharmaceuticals$0.06-0.9%$0.06$0.03▼$0.08$629K1.5270,530 shs5,600 shsUPCUniverse Pharmaceuticals$3.95-1.6%$3.69$2.51▼$600.00$2.22M1.44253,750 shs11,945 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%0.00%0.00%-97.76%BPTSYBiophytis0.00%0.00%0.00%+44.93%-60.71%HEPAHepion Pharmaceuticals0.00%-28.85%-11.90%-28.20%-99.85%UPCUniverse Pharmaceuticals0.00%+12.96%+12.48%+1.52%-98.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.10$660K1.1286,634 shs16,292 shsBPTSYBiophytis$2.00$1.83$1.33▼$5.97$702K0.861,668 shsN/AHEPAHepion Pharmaceuticals$0.06-0.9%$0.06$0.03▼$0.08$629K1.5270,530 shs5,600 shsUPCUniverse Pharmaceuticals$3.95-1.6%$3.69$2.51▼$600.00$2.22M1.44253,750 shs11,945 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%0.00%0.00%-97.76%BPTSYBiophytis0.00%0.00%0.00%+44.93%-60.71%HEPAHepion Pharmaceuticals0.00%-28.85%-11.90%-28.20%-99.85%UPCUniverse Pharmaceuticals0.00%+12.96%+12.48%+1.52%-98.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics 3.00Buy$23.0015,664.22% UpsideBPTSYBiophytis 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora Therapeutics$892K0.74N/AN/A($36.43) per share0.00BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AUPCUniverse Pharmaceuticals$19.29M0.12N/AN/A$163.50 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/ABPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%11/12/2025 (Estimated)UPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.050.05BPTSYBiophytisN/A0.41N/AHEPAHepion PharmaceuticalsN/A1.301.30UPCUniverse PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%BPTSYBiophytis0.05%HEPAHepion Pharmaceuticals17.24%UPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics51.08%BPTSYBiophytis3.70%HEPAHepion Pharmaceuticals0.06%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics1204.52 million2.21 millionOptionableBPTSYBiophytis30351,000338,000N/AHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataUPCUniverse Pharmaceuticals220563,000731,000Not OptionableUPC, BIOR, HEPA, and BPTSY HeadlinesRecent News About These CompaniesUniverse Pharmaceuticals Reports Decline in Financial Performance Amid Regulatory ChangesAugust 31, 2025 | theglobeandmail.comUniverse Pharmaceuticals Inc. (UPC) Stock Price Today - WSJAugust 7, 2025 | wsj.comPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comUniverse Pharmaceuticals proposes revised share consolidationFebruary 11, 2025 | msn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest ReportFebruary 10, 2025 | benzinga.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 6, 2025 | finanznachrichten.deUPC’s Unexpected Plunge: What’s Next?February 5, 2025 | bovnews.comBUniverse Pharmaceuticals gets Nasdaq delisting noticeFebruary 4, 2025 | markets.businessinsider.comUniverse Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share PriceFebruary 3, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 3, 2025 | globenewswire.comUniverse Pharmaceuticals announces shareholder meetingJanuary 30, 2025 | msn.comUniverse Pharmaceuticals stock hits 52-week low at $0.48 amid steep declineJanuary 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025TJX Stock Price Hits Fresh High, Signals More Highs to FollowBy Thomas Hughes | August 22, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025UPC, BIOR, HEPA, and BPTSY Company DescriptionsBiora Therapeutics NASDAQ:BIORBiora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Biophytis NASDAQ:BPTSY$2.00 0.00 (0.00%) As of 09/12/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Hepion Pharmaceuticals NASDAQ:HEPA$0.06 0.00 (-0.90%) As of 01:11 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Universe Pharmaceuticals NYSE:UPC$3.95 -0.06 (-1.60%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
